Total submissions: 16
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV000244124 | SCV000307976 | likely benign | not specified | 2015-12-30 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001697691 | SCV000524848 | likely benign | not provided | 2021-01-12 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000542823 | SCV000651181 | benign | Myofibrillar myopathy 5; Distal myopathy with posterior leg and anterior hand involvement; Hypertrophic cardiomyopathy 26; Dilated Cardiomyopathy, Dominant | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Phosphorus, |
RCV000578028 | SCV000679853 | likely benign | Primary dilated cardiomyopathy | 2017-08-01 | criteria provided, single submitter | clinical testing | |
Phosphorus, |
RCV000578104 | SCV000679854 | likely benign | Distal myopathy with posterior leg and anterior hand involvement | 2017-08-01 | criteria provided, single submitter | clinical testing | |
Phosphorus, |
RCV000577968 | SCV000679855 | likely benign | Hypertrophic cardiomyopathy | 2017-08-01 | criteria provided, single submitter | clinical testing | |
Phosphorus, |
RCV000578026 | SCV000679856 | likely benign | Myofibrillar myopathy 5 | 2017-08-01 | criteria provided, single submitter | clinical testing | |
Phosphorus, |
RCV000578102 | SCV000679857 | likely benign | Hypertrophic cardiomyopathy 26 | 2017-08-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002418082 | SCV002677977 | likely benign | Cardiovascular phenotype | 2019-03-04 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Ce |
RCV001697691 | SCV004161056 | likely benign | not provided | 2024-02-01 | criteria provided, single submitter | clinical testing | FLNC: BP4, BP7, BS1 |
CHEO Genetics Diagnostic Laboratory, |
RCV003486791 | SCV004240679 | likely benign | Cardiomyopathy | 2023-06-06 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV001697691 | SCV005226720 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Clinical Genetics, |
RCV000244124 | SCV001926240 | benign | not specified | no assertion criteria provided | clinical testing | ||
Genome Diagnostics Laboratory, |
RCV001697691 | SCV001926736 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000244124 | SCV001953042 | benign | not specified | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV001697691 | SCV001967058 | likely benign | not provided | no assertion criteria provided | clinical testing |